CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
Celebrate National Blood Donor Month throughout January by inviting eligible individuals to donate b...
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...
Dr. Buff Mair is the new CTS Medical Director and replaces Dr. German Leparc who retired at the begi...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
On January 25, 2021, CTS implements the Ortho VIP viral marker testing platform. Conversion from the...
As the US coast prepares for Hurricane Florence to make landfall, we have received importan...